Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).
Lori J. Wirth, MD
Lori J. Wirth, MD, is the medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital.
Articles by Lori J. Wirth, MD
Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.
Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.
A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.
Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.
Dr Lori Wirth highlights exciting clinical trials in advanced RAI-R-DTC and investigational agents to look out for in the future.
Lori Wirth, MD, provides a brief overview of advanced radioactive iodine-refractory differentiated thyroid cancer, or RAI-R-DTC.
Lori J. Wirth, MD, discusses a new assay with the ability to perform DNA and RNA sequencing to better detect gene fusions.
Lori J. Wirth, MD, explains the role of NTRK inhibitor in TRK fusion-positive thyroid cancer treatment.
Lori J. Wirth, MD, discusses sequencing therapies for patients with NTRK fusion–positive advanced thyroid cancer.
Lori J. Wirth, MD, discusses the treatment options now available for patients with iodine-refractory differentiated thyroid cancer.
Lori Wirth, MD, discusses her experience with NTRK-targeted therapies for patients with thyroid cancer.
Lori Wirth, MD, discusses the subanalysis of patients with thyroid cancer with NTRK fusion mutations in clinical trials for larotrectinib.
Lori Wirth, MD, discusses unmet needs and future considerations in the management of differentiated thyroid cancer.
Lori Wirth, MD, reviews key efficacy data from the post hoc analysis of the SELECT trial investigating the use of lenvatinib in patients with lung metastases.
An overview of how SELECT trial data affected clinical treatment practice for patients with differentiated thyroid cancer.
Medical oncologist Lori Wirth, MD, discusses treatment options for patients with radioiodine-refractory metastatic disease.
Lori Wirth, MD, discusses treatment options and potential adverse effects for differentiated thyroid cancer.
Lori Wirth, MD, provides an overview and diagnosis consideration of differentiated thyroid cancer and its related subtypes.
A discussion on the management of a 64-year-old man with differentiated thyroid cancer, with special consider of the phase 3 SELECT trial regimen.
